The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology Research Programs
The Division of Cancer Biology (DCB) at the National Cancer Institute (NCI) announces the opportunity for current awardees of DCB led programs to apply for supplemental funding to support collaborative research projects. DCB led or co-led programs appropriate for this opportunity include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Collaborative projects can include investigators within one consortium, across consortia, and/or may include investigators who are not currently supported by the DCB research programs listed above but are collaborating with a member of a DCB led or co-led consortium (i.e. Associate Members). The programmatic goals of each research program may differ; therefore, it is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.
Collaborative projects must include at least one investigator not named as key personnel on the parent award who brings unique expertise that is required for the proposed project. The proposed research plan must be within the overall scope of the active parent U54, U24, U01, R37 and/or R01 award and align with the mission of the Division of Cancer Biology. All potential applicants are highly encouraged to contact their NCI Program Director to discuss the planned collaboration and application.
Deadline: April 20, 2023
- Awardees/Applicant(s) must hold an active grant or cooperative agreement in the ARTNet, CSBC, TEC, CCBIR, MetNet, OAC, OMF, PSRC, PDMC, PS-ON, Program on the Origins of Gastroesophageal Cancers, or TBEL, as awarded under the funding opportunity announcements (FOAs) listed below.
- PAR-16-059; PAR-16-131; PAR-16-344; PAR-17-171; PAR-17-245; PAR-19-101; PAR-19-113; PAR-19-287; RFA-CA-20-029; RFA-CA-20-040; RFA-CA-20-041; RFA-CA-20-042; PAR-20-131; RFA-CA-21-002; RFA-CA-21-026; RFA-CA-21-027; RFA-CA-21-048; RFA-CA-21-049; RFA-CA-21-052; RFA-CA-21-053; RFA-CA-21-054; RFA-CA-21-055; PAR-22-099; PAR-22-147;
- To be eligible, the parent award must be able to receive funds in FY23 and be active throughout the 1-year project period. The parent award must not be in an extension period (e.g., cost or no-cost extension).
- Collaborative projects must include at least one investigator not named as key personnel on the parent award who brings unique expertise that is required for the proposed project.
- For supplements to parent awards that include multiple program directors/principal investigators (PD/PIs), the supplement may be requested by any or all of the PD/PIs on that award (in accordance with the existing leadership plan) and must be submitted by the awardee institution of the parent award.
- One Administrative Supplement application may be submitted by each U01 or R01 parent award. If more than one application is submitted from a given U01 or R01 parent award all applications will be administratively withdrawn from consideration.
- Up to two Administrative Supplement applications may be submitted by each U24 and U54 parent award. If more than two applications are submitted from a given U24 or U54 parent award all applications will be administratively withdrawn from consideration.
- Early Stage Investigators (ESIs) are encouraged to apply as part of collaborative teams.
- Collaborations with foreign institutions are allowed, but investigators must provide a justification for the collaboration. Please note that some foreign collaborations will require U.S. State Department approval by the NCI, and that may delay receipt of funding.